Stewart-Treves Syndrome Treatment Market: Introduction
• Stewart-Treves syndrome is very rare and a deadly condition. This disorder is characterized by the occurrence of cutaneous angiosarcoma, which grows in long-standing chronic lymphedema. At present, only about 400 cases have been reported cases of the Stewart-Treves syndrome. This syndrome is also called radical mastectomy. Its global incidence rate is between 0.03%–0.5%.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B...
• The syndrome is observed in women who have grown lymphedema in upper extremity inferior to axillary lymph node dissection after the breast cancer surgery. It is exceptionally uncommon in lower extremities due to result of idiopathic chronic lymphedema. Diagnosis is very important for angiosarcoma due to chances of metastatic spread and poor prognosis. For instance, poor prognostic aspects include depth invasion (greater than 3 mm) and large tumor size. Usually, 25% to 45% of patients who are diagnosed with angiosarcoma already have distant metastasis, contributing to the belligerent nature of this neoplasm. These can affect numerous locations, such as breasts, skin, soft tissue, and liver. Currently, it occurs in 0.03% of patients surviving 11 or more years after radical mastectomy.
Request for Covid-19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=c...
Key Drivers of Global Stewart-Treves Syndrome Treatment Market
• Global Stewart-Treves syndrome treatment market is expected to grow rapidly in the near future due to increase in the adoption of unhealthy lifestyle, which leads to change in sleeping as well as eating habits
• Rise in demand for personalized medicines, as well as radiotherapy and mastectomy for breast cancer, which may lead to the Stewart-Treves syndrome, is expected to drive the global Stewart-Treves syndrome treatment market
• Treatment for Stewart-Treves syndrome is amputation of the affected part; for instance, limb or large resection of the part. Tumors, which have advanced locally or which have metastasized are usually treated with polychemotherapy or monotherapy. However, research findings suggest that radiation therapy and chemotherapy have not been observed to improve survival of the patient decently. In cases of upper limbs, amputation is preferred.
Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=E...
North America to Hold Major Share of Global Stewart-Treves Syndrome Treatment Market
• Due to technological advancements and high adoption rate, North America dominates the global Stewart-Treves syndrome treatment market, followed by Europe and Asia Pacific. Asia Pacific is expected to be the most lucrative market for Stewart-Treves syndrome treatment in the near future due to developing medical infrastructure, medical tourism, rise in acceptance of technologically advanced surgical procedures, and increase in government initiatives.
Key Players Operating in Global Market
The global Stewart-Treves syndrome treatment market is highly consolidated with major manufacturers adopting various research strategies to gain market share. Only a few companies have their presence in the market, while others have their products in the pipeline.
Some of the key players operating in the global Stewart-Treves syndrome treatment market are:
• Smith & Nephew plc
• Pfizer, Inc.
• EISAI Inc.
• Sanofi-Aventis
• Sun Pharmaceuticals
• Cadila Healthcare Ltd